TW EN

scroll

Go Top

Overview

TCTC

Promote the development of the domestic biotech and pharmaceutical industry by verifying the effectiveness and safety of products and enabling their entry into international markets. By attracting international pharmaceutical companies to conduct clinical trials in Taiwan, we will not only benefit patients but also accumulate experience in conducting large-scale clinical trials for domestic medical institutions and medical personnel, further promoting the development of the domestic biotech and pharmaceutical industry. Encourage domestic medical personnel to initiate clinical trials, propose solutions according to the needs of patients, improve patient prognoses, and promote the update and development of related medical policies. Through the implementation of the above plan, we expect to make significant contributions to the treatment and prevention of infectious diseases in Taiwan and globally.

Strengths

TCTC

  • Diagnosis and treatment of emerging infectious diseases, such as new influenza, COVID-19, monkeypox, etc. Vaccine development for emerging infectious diseases, such as COVID-19 and dengue fever.
  • To solve unsolved problems in nosocomial infections and medical routines, such as the treatment of multi-drug-resistant bacterial infections and invasive mold infections, the development of rapid influenza screening reagents, and the application of next-generation sequencing tools for bacterial diagnosis.
  • Use big data to analyze the pathogenic infection process and treatment model, and provide real-world evidence through real-world data research.

Major Achievements

TCTC

Clinical trial International cooperation

  • We participated in the early clinical trial design and implementation of the Medigen COVID-19 vaccine development. The Medigen protein vaccine has been authorized for emergency use in Taiwan FDA and has been available for public vaccination. The trial results were published in Lancet Respiratory Medicine and received international recognition (including a published interview in the journal Nature). It was also selected by the WHO and the Bill & Melinda Gates Foundation for sponsorship in the third phase of the trial. The technology transfer license was granted to the WHO on August 30, 2023.

  • Participate " An interventional, efficacy and safety, phase 2, randomized, double-bland, 2-arm study to investigate a repeat 5-day course of NIRMATRELVIR/RITONAVIR compared to placebo/ritonavir in participants at least 12 years of age with rebound of COVID-19 symptoms and repaid antigen test positivity " clinical trial, implemented by Pfizer to assist the US CDC., Taiwan recruited a total of 7 subjects, ranking second in the country after the United States.
  • Participation "A Phase III, adjudicator-blinded, randomized study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisomeR followed by standard of care (SOC) in patients with invasive fungal disease ( IFD) caused by Aspergillus species" clinical trial which is conducted by F2G Ltd. in the UK and Austria, the experimental drug olorofim is an oral dosage form and is expected to become an effective second-line alternative drug.
 

Economic benefits

The domestic COVID-19 epidemic has spread in Taiwan since March 2020. Dr. Hsieh Szu-Min assisted vaccine companies in developing and providing safe, protective and effective vaccines. The cumulative number of high-end administration of the first, second and third doses exceeded 2.68 million. doses (statistics as of May 2012), the accumulated experience can be continued and passed on, giving the country the ability to develop its own vaccines to respond to the risks of emerging infectious diseases.

 

Social and other aspects

Domestic vaccine companies develop and provide safe, protective and effective vaccines for the public to administer. According to the Department of Disease Control and Prevention's "COVID-19 Vaccine Taiwan Data and Estimates" (data source: https://www.aweb.tpin.idv. tw/COVID-19/vaccine.php), the cumulative number of high-end doses of the first, second and third doses exceeded 2.68 million (statistics as of May 2012).

Members

TCTC

National Taiwan University, College of Medicine/ National Taiwan University Hospital

Kaohsiung Medical University College of Medicine/ Kaohsiung Medical University Chung-Ho Memorial Hospital

Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital

Taichung Veterans General Hospital/ National Chung Hsing University

National Taiwan University/ National Taiwan University Hospital

National Taiwan University, College of Medicine / National Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University, Cancer Center

National Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University Hospital

National Taiwan University, Cancer Center

Contact Information

c-IRB

Yu-Chung Chuang / Yi Hsin Liu

Email:yuchung@ntuh.gov.tw / liu16822@ntuh.gov.tw

TEL:(02)23123456 ext #265929